US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Conexeu Sciences Inc.

3.89

+0.440012.75%

Post-market: 4.000.1061+2.73%19:57 EDT

Volume:427.99K

Turnover:1.69M

Market Cap:109.72M

PE:-7.83

High:4.22

Open:3.50

Low:3.47

Close:3.45

52wk High:18.79

52wk Low:3.05

Shares:28.21M

Float Shares:15.54M

Volume Ratio:1.94

T/O Rate:2.75%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4970

EPS(LYR):-0.3104

ROE:-332.94%

ROA:-170.73%

PB:18.75

PE(LYR):-12.53

Loading ...

Overview Company News Filings

Conexeu Sciences Shares Rise on Advancement of Tissue Restoration Platform

Conexeu provides update on FDA 510 premarket notification for Ten Minute Tissue

Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

THOMSON REUTERS

Conexeu Sciences Issues 762,608 Unregistered Shares at Us$2.3 in Warrant Exercise Incentive Program

Conexeu Sciences to Present at Nasdaq/LD Micro Summit Series

Conexeu Sciences Sets September and October 2026 Conference Schedule

Conexeu Says CXU Preclinical Program Completes 12-Month P.r.o.o.f. Phase, Meets Objectives

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Conexeu Highlights ECM-Based Regenerative Platform Ahead of 2026 Aesthetics Symposium

Conexeu Sciences CMO Presents on Extracellular Matrix Role in Tissue Regeneration at Laser & Cosmetic Surgery Symposium

Conexeu Sciences Announces Press Release Availability

Conexeu Sciences Completes 12-month Preclinical Study for CXU Tissue-restoration Platform

Conexeu Sciences Notifies Availability of Press Release

Conexeu Sciences Director Andrew Costa Files Initial Beneficial Ownership Statement

Alert Tagged to Multiple Companies from a Research Report Withdrawn

The Aesthetics Giants Just Confirmed “ozempic Face” is Real — and a Newly Public Regenerative Player Wants to Compete for It

THOMSON REUTERS

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Conexeu Sciences director Ana Lucia Bastiani-Posner files initial beneficial ownership statement

Conexeu Sciences director, 10% owner Lynn Sebastian Purcell reports $162,000 common share purchase

Conexeu Sciences Initiated at Buy by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CNXU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CNXU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNXU\",,,,,undefined,":{"symbol":"CNXU","market":"US","secType":"STK","nameCN":"Conexeu Sciences Inc.","latestPrice":3.89,"timestamp":1791576000000,"preClose":3.45,"halted":0,"volume":427986,"hourTrading":{"tag":"盘后","latestPrice":3.9961,"preClose":3.89,"latestTime":"19:57 EDT","volume":4908,"amount":19306.2941,"timestamp":1791590230907,"change":0.1061,"changeRate":0.027275,"amplitude":0.046041},"delay":0,"changeRate":0.12753623188405794,"floatShares":15541501,"shares":28206698,"eps":-0.497,"marketStatus":"Market Closed","change":0.44,"latestTime":"10-09 16:00:00 EDT","open":3.5,"high":4.2183,"low":3.4684,"amount":1689770.04534,"amplitude":0.217362,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.497,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1779336000000,"exchange":"NASDAQ","adjPreClose":3.45,"preHourTrading":{"tag":"盘前","latestPrice":3.528,"preClose":3.45,"latestTime":"08:26 EDT","volume":218,"amount":777.6240068,"timestamp":1791548783539,"change":0.078,"changeRate":0.022609,"amplitude":0.098551},"postHourTrading":{"tag":"盘后","latestPrice":3.9961,"preClose":3.89,"latestTime":"19:57 EDT","volume":4908,"amount":19306.2941,"timestamp":1791590230907,"change":0.1061,"changeRate":0.027275,"amplitude":0.046041},"volumeRatio":1.935584533380017},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNXU\",,,,,undefined,":{"symbol":"CNXU","floatShares":15541501,"roa":"-170.73%","roe":"-332.94%","lyrEps":-0.310358,"volumeRatio":1.935584533380017,"shares":28206698,"dividePrice":0,"high":4.2183,"amplitude":0.217362,"preClose":3.45,"low":3.4684,"week52Low":3.0501,"pbRate":"18.75","week52High":18.7915,"institutionHeld":0,"latestPrice":3.89,"eps":-0.497,"divideRate":0,"volume":427986,"delay":0,"ttmEps":-0.497,"open":3.5,"prevYearClose":13.5,"prevWeekClose":3.1,"prevMonthClose":3.57,"prevQuarterClose":3.57,"fiveDayClose":3.1,"twentyDayClose":4.46,"sixtyDayClose":10.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNXU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-09-14","symbol":"CNXU","fiscalQuarterEnding":"2026/07","expectedEps":-0.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1789358400000,"reportTimeType":"post","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNXU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNXU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1782187200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CNXU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CNXU","date":"2026-10-09","current":-7.826962,"percent":0.968421,"low":-79.55424,"twenty":-53.303701,"median":-33.194451,"eighty":-18.474404,"high":-6.417374,"avg":-34.688351,"sd":18.65648,"marketCap":97313108},"quantilePoints":[{"date":"2026-05-22","current":-61.707651,"twenty":-61.707651,"median":-61.707651,"eighty":-61.707651,"marketCap":330278847},{"date":"2026-05-29","current":-54.672884,"twenty":-65.607461,"median":-64.327983,"eighty":-60.300698,"marketCap":292626553},{"date":"2026-06-05","current":-75.541118,"twenty":-76.3343,"median":-65.838806,"eighty":-60.437616,"marketCap":404319936},{"date":"2026-06-12","current":-57.26961,"twenty":-72.783868,"median":-65.815199,"eighty":-60.63119,"marketCap":306525051},{"date":"2026-06-18","current":-61.471585,"twenty":-72.022319,"median":-64.327983,"eighty":-56.504756,"marketCap":329015347},{"date":"2026-06-26","current":-37.989619,"twenty":-69.581868,"median":-61.589618,"eighty":-54.125211,"marketCap":273470132},{"date":"2026-07-02","current":-38.138306,"twenty":-67.458218,"median":-61.182094,"eighty":-40.651122,"marketCap":274540465},{"date":"2026-07-10","current":-36.837292,"twenty":-66.325102,"median":-57.26961,"eighty":-39.424451,"marketCap":265175050},{"date":"2026-07-17","current":-39.067602,"twenty":-65.494149,"median":-53.988293,"eighty":-38.257256,"marketCap":281230048},{"date":"2026-07-24","current":-34.012232,"twenty":-64.738738,"median":-41.558115,"eighty":-37.945013,"marketCap":244838719},{"date":"2026-07-31","current":-32.822733,"twenty":-64.002212,"median":-40.591647,"eighty":-36.004643,"marketCap":236276053},{"date":"2026-08-07","current":-31.484547,"twenty":-62.500833,"median":-39.94114,"eighty":-34.153485,"marketCap":226643055},{"date":"2026-08-14","current":-29.625955,"twenty":-61.660438,"median":-39.067602,"eighty":-32.859905,"marketCap":213263890},{"date":"2026-08-21","current":-35.053043,"twenty":-61.471585,"median":-38.101134,"eighty":-33.023461,"marketCap":252331051},{"date":"2026-08-28","current":-26.168974,"twenty":-61.355789,"median":-37.989619,"eighty":-31.008748,"marketCap":188378643},{"date":"2026-09-04","current":-19.589559,"twenty":-60.536268,"median":-36.985979,"eighty":-29.090681,"marketCap":141016399},{"date":"2026-09-11","current":-15.798031,"twenty":-59.110925,"median":-36.446988,"eighty":-28.547972,"marketCap":113722902},{"date":"2026-09-18","current":-20.767449,"twenty":-57.26961,"median":-35.313246,"eighty":-27.023926,"marketCap":149495499},{"date":"2026-09-25","current":-8.197678,"twenty":-55.357476,"median":-34.88577,"eighty":-25.927357,"marketCap":111698524},{"date":"2026-10-02","current":-6.872801,"twenty":-54.672884,"median":-33.752029,"eighty":-19.589559,"marketCap":93646237},{"date":"2026-10-09","current":-7.141916,"twenty":-53.303701,"median":-33.194451,"eighty":-18.474404,"marketCap":97313108}],"updateTime":1791693459670},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNXU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673231068","title":"Conexeu Sciences Shares Rise on Advancement of Tissue Restoration Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2673231068","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673231068?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:13","pubTimestamp":1791313980,"startTime":"0","endTime":"0","summary":"Shares of Conexeu Sciences rose after the medical device and regenerative medicine company reported progress for its CXU tissue restoration platform.The stock was up 11% to $3.45 in Tuesday afternoon trading. Shares have traded in range of $3.05 to $18.79 since their debut on Nasdaq via a direct listing.The company said it has advanced manufacturing scale-up, regulatory testing and preclinical work supporting a planned 510 submission to the Food and Drug Administration in the first quarter of 2027.Multiple scaled-up batches of CXU material met company specifications for key material characteristics and product performance measures, the company said.CXU is a collagen-based extracellular matrix platform.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Conexeu Sciences Shares Rise on Advancement of Tissue Restoration Platform","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051138","title":"Conexeu provides update on FDA 510 premarket notification for Ten Minute Tissue","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051138?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:12","pubTimestamp":1791292341,"startTime":"0","endTime":"0","summary":"Conexeu Sciences (CNXU) provided an update on the regulatory and manufacturing program supporting its planned FDA 510 premarket notification for Te...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conexeu-provides-update-on-fda-510-premarket-notification-for-ten-minute-tissue-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conexeu-provides-update-on-fda-510-premarket-notification-for-ten-minute-tissue-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","EES","BK4585","CNXU","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673605985","title":"Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2673605985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673605985?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:30","pubTimestamp":1791289802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA5RT5KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666515287","title":"Conexeu Sciences Issues 762,608 Unregistered Shares at Us$2.3 in Warrant Exercise Incentive Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666515287","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666515287?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:32","pubTimestamp":1789072347,"startTime":"0","endTime":"0","summary":"Conexeu Sciences issues 762,608 unregistered shares at US$2.3 in warrant exercise incentive programConexeu Sciences issued 1,448,368 unregistered common shares from June 18 to Sept. 4, triggering a Fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL4NVDQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664485945","title":"Conexeu Sciences to Present at Nasdaq/LD Micro Summit Series","url":"https://stock-news.laohu8.com/highlight/detail?id=2664485945","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664485945?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:32","pubTimestamp":1788265947,"startTime":"0","endTime":"0","summary":"Conexeu Sciences to present at Nasdaq/LD Micro Summit SeriesConexeu will attend the Nasdaq / LD Micro Summit Series on Sept. 9, 2026 in San Francisco.Management is also scheduled for the H.C. Wainwrig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLcfCHgF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00BQXX3D17.EUR","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","BK4585","BK4139","LU2210150020.SGD","BK4112","CNXU","BCDF","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","BK4588","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851209","title":"Conexeu Sciences Sets September and October 2026 Conference Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851209","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851209?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:30","pubTimestamp":1788265800,"startTime":"0","endTime":"0","summary":"RENO, Nev., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restora","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354163/0/en/conexeu-sciences-sets-september-and-october-2026-conference-schedule.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660674844","title":"Conexeu Says CXU Preclinical Program Completes 12-Month P.r.o.o.f. Phase, Meets Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2660674844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660674844?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:55","pubTimestamp":1787057729,"startTime":"0","endTime":"0","summary":"Conexeu says CXU preclinical program completes 12-month P.R.O.O.F. phase, meets objectivesConexeu disclosed completion of the 12-month P.R.O.O.F. phase in its CXU preclinical program for an ECM-based ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL5hTz5g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467389","title":"Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467389","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467389?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:30","pubTimestamp":1787056200,"startTime":"0","endTime":"0","summary":"Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu’s CXU Platform Highli","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346816/0/en/conexeu-sciences-sees-a-new-category-forming-in-medical-aesthetics-as-research-turns-to-regeneration.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658505916","title":"Conexeu Highlights ECM-Based Regenerative Platform Ahead of 2026 Aesthetics Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2658505916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658505916?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:02","pubTimestamp":1786456969,"startTime":"0","endTime":"0","summary":"Conexeu Sciences, Inc. ( ($CNXU) ) just unveiled an announcement. Conexeu Sciences, a regenerative tissue platform specialist, is building its CXU ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/conexeu-highlights-ecm-based-regenerative-platform-ahead-of-2026-aesthetics-symposium?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/conexeu-highlights-ecm-based-regenerative-platform-ahead-of-2026-aesthetics-symposium?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658368918","title":"Conexeu Sciences CMO Presents on Extracellular Matrix Role in Tissue Regeneration at Laser & Cosmetic Surgery Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2658368918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658368918?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:32","pubTimestamp":1786451547,"startTime":"0","endTime":"0","summary":"Conexeu Sciences CMO presents on extracellular matrix role in tissue regeneration at Laser & Cosmetic Surgery symposiumConexeu will present at the Controversies & Conversations in Laser & Cosmetic Sur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8gBbQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","BCDF","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","CNXU","BK4112","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651110567","title":"Conexeu Sciences Announces Press Release Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2651110567","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651110567?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:31","pubTimestamp":1784032311,"startTime":"0","endTime":"0","summary":"Conexeu Sciences announces press release availabilityConexeu released an update on its CXU tissue-restoration platform, citing completion of a 12-month P.R.O.O.F. preclinical study.Focus is large-volu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDLc1zG4s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4585","SG9999014039.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","IE00BN0W2T93.GBP","LU2095319765.USD","NDAQ","BCDF","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","CNXU","SG9999014021.USD","BK4588","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649195853","title":"Conexeu Sciences Completes 12-month Preclinical Study for CXU Tissue-restoration Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2649195853","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649195853?lang=en_us&edition=fundamental","pubTime":"2026-07-08 05:13","pubTimestamp":1783458831,"startTime":"0","endTime":"0","summary":"Conexeu Sciences completes 12-month preclinical study for CXU tissue-restoration platformConexeu completed its 12-month P.R.O.O.F preclinical study for the CXU platform, a key milestone ahead of plann","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL92bnq6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649938802","title":"Conexeu Sciences Notifies Availability of Press Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2649938802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649938802?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:01","pubTimestamp":1783429306,"startTime":"0","endTime":"0","summary":"Conexeu Sciences notifies availability of press releaseConexeu published a release reporting completion of its 12-month P.R.O.O.F preclinical program for the CXU platform.Results met study objectives ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL8HbHGg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","BCDF","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","CNXU","BK4112","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378736","title":"Conexeu Sciences Director Andrew Costa Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378736","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647378736?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:15","pubTimestamp":1782728131,"startTime":"0","endTime":"0","summary":"Conexeu Sciences director Andrew Costa files initial beneficial ownership statementConexeu Sciences director Andrew Costa reported holding options to buy 50,000 common shares at USD 2.3 per share in a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL5Wm6lz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646980570","title":"Alert Tagged to Multiple Companies from a Research Report Withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2646980570","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646980570?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:46","pubTimestamp":1782395175,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert tagged to multiple companies from a research report withdrawnAn alert from a Biotech Insider's research report on weight loss drugs was inadvertently published and tagged to AbbVie IncA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA8DWXYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443382.USD","LU1934455277.USD","SG9999003800.SGD","SG9999011175.SGD","LU1989772840.SGD","ABBV","LU0985320562.USD","LU0114720955.EUR","LU2133065610.SGD","IE00BDGV0183.EUR","LU1989771016.USD","SG9999015952.SGD","LU2347655156.SGD","LU0868494617.USD","INMD","LU0198837287.USD","IE000BZT7R73.USD","LU2468319806.SGD","CNXU","IE00B19Z3581.USD","IE0004445239.USD","LU1244550221.USD","LU1244550577.SGD","LU0795875169.SGD","ESTA","IE00BFTCPJ56.SGD","LU0820561909.HKD","IE00B19Z3B42.SGD","LU0965509101.SGD","LU1934455863.HKD","IE00BBT3K403.USD","LU1003077747.HKD","LU1551013425.SGD","LU1839511570.USD","LU0203345920.USD","BK4585","LU2237443978.SGD","LU0029864427.USD","LU2129689514.USD","SG9999015945.SGD","LU0098860793.USD","LU0511384066.AUD","LU0965509283.SGD","BK4550","BK4588","LU0058720904.USD","LU0289739343.SGD","BK4082","LU1732799900.SGD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646163803","title":"The Aesthetics Giants Just Confirmed “ozempic Face” is Real — and a Newly Public Regenerative Player Wants to Compete for It","url":"https://stock-news.laohu8.com/highlight/detail?id=2646163803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646163803?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:04","pubTimestamp":1782392640,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA8DWXYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0965509283.SGD","LU0511384066.AUD","ESTA","IE0004445239.USD","LU2237443978.SGD","LU1839511570.USD","LU2468319806.SGD","LU1934455863.HKD","LU1003077747.HKD","LU0820561909.HKD","LU2347655156.SGD","LU2129689514.USD","SG9999011175.SGD","LU1244550221.USD","LU0289739343.SGD","LU1244550577.SGD","LU1732799900.SGD","IE00B19Z3581.USD","LU0965509101.SGD","BK4585","BK4588","LU2087621335.USD","LU1551013425.SGD","LU1934455277.USD","SG9999003800.SGD","LU0203345920.USD","IE00B19Z3B42.SGD","INMD","ABBV","LU0098860793.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","IE000BZT7R73.USD","BK4550","LU2133065610.SGD","SG9999015952.SGD","LU0198837287.USD","LU2237443382.USD","CNXU","LU0795875169.SGD","LU0114720955.EUR","LU0985320562.USD","LU1989772840.SGD","SG9999015945.SGD","IE00BDGV0183.EUR","IE00BBT3K403.USD","BK4082","LU0868494617.USD","LU1989771016.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646480850","title":"Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2646480850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646480850?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:30","pubTimestamp":1782390600,"startTime":"0","endTime":"0","summary":"Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Leadership team   Conexeu Sciences' leadership team celebrates the opening of the company's new...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317518/0/en/Conexeu-Sciences-Opens-Vancouver-R-D-Facility-to-Advance-Regenerative-Tissue-Platform.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645630558","title":"Conexeu Sciences director Ana Lucia Bastiani-Posner files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2645630558","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645630558?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:52","pubTimestamp":1782265935,"startTime":"0","endTime":"0","summary":"Conexeu Sciences director Ana Lucia Bastiani-Posner reported options to buy 50,000 common shares at USD 2.3, expiring Feb. 9, 2031.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL2vsrHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645850972","title":"Conexeu Sciences director, 10% owner Lynn Sebastian Purcell reports $162,000 common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2645850972","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645850972?lang=en_us&edition=fundamental","pubTime":"2026-06-24 08:16","pubTimestamp":1782260190,"startTime":"0","endTime":"0","summary":"Conexeu Sciences disclosed a purchase by director, 10% owner Lynn Sebastian Purcell, held indirectly through OnePointTwo Capital Ventures.The filing shows an acquisition of 202,500 common shares at USD 0.8, lifting indirect holdings to 2,734,240 shares.OnePointTwo also bought 202,500 warrants for USD 0.001 each, exercisable at USD 2.3, with warrant holdings rising to 625,000.The filing also reports the exercise of 202,500 warrants at USD 0.8, leaving 625,000 warrants beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL5fjgcZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Conexeu Sciences director, 10% owner Lynn Sebastian Purcell reports $162,000 common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645203029","title":"Conexeu Sciences Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645203029","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645203029?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:08","pubTimestamp":1782126480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNXU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 07:08 ET (11:08 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}